一株具有抑制效果的抗PRRSV Nsp4蛋白单克隆抗体及其应用
By preparing the monoclonal antibody 1C11 targeting the PRRSV Nsp4 protein, the challenges of PRRSV diagnosis and vaccine immunization strategies have been solved. This has enabled the detection of different lineages of the virus and the inhibition of viral replication, providing a basis for the development of early PRRSV diagnostic tools and antiviral agents.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANGHAI VETERINARY RESEARCH INSTITUTE CAAS (CHINESE ANIMAL HEALTH & EPIDEMIOLOGY CENTER SHANGHAI BRANCH)
- Filing Date
- 2025-12-26
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies are insufficient for effective diagnosis, and vaccine immunization strategies are inadequate to address the wide range of antigenic variations in PRRSV, making accurate diagnosis and control of PRRSV difficult.
A monoclonal antibody 1C11 targeting the PRRSV Nsp4 protein was prepared, which can specifically recognize all PRRSV-2 representative strains and some PRRSV-1 representative strains, and has a certain inhibitory effect on viral replication. By identifying the novel antigenic epitope 123ITEAGELV130 in the Nsp4 protein, the detection of different lineages of the virus was achieved.
It provides an effective tool for the early diagnosis of PRRSV, enhances the understanding of the antigenic properties of the Nsp4 protein, provides a basis for the development of epitope-based diagnostic tools, and demonstrates the potential of monoclonal antibodies targeting the Nsp4 protein in antiviral agents.
Smart Images
Figure CN121698995B_ABST